[1] He Yi, Xiao Guomin,. Preparation and in vitro release studiesof thymosin-loaded PLA microspheres [J]. Journal of Southeast University (English Edition), 2007, 23 (2): 294-297. [doi:10.3969/j.issn.1003-7985.2007.02.028]

Copy

Preparation and in vitro release studiesof thymosin-loaded PLA microspheres()

Share：

Journal of Southeast University (English Edition)[ISSN:1003-7985/CN:32-1325/N]

Volumn:

23

Issue:

2007 2

Page:

294-297

Research Field:

Biological Science and Medical Engineering

Publishing date:

2007-06-30

Info

Title:

Preparation and in vitro release studiesof thymosin-loaded PLA microspheres

Author(s):

He Yi;  Xiao Guomin

School of Chemistry and Chemical Engineering, Southeast University, Nanjing 210096, China

Keywords:

thymosin;  polylactic acid;  microsphere;  in vitro release

PACS:

R927.2

DOI:

10.3969/j.issn.1003-7985.2007.02.028

Abstract:

To obtain a kind of convenient oral dosage form of protein, which can be fully absorbed and is efficient and safe, the thymosin-loaded PLA(polylactic acid)microspheres are prepared by the emulsification-solvent evaporation method and the orthogonal design is used to optimize the technology of preparation.The form of the medicament microspheres of thymosin are proved by differential thermal analysis(DTA). The drug content is determined by the Lowry method, and the package ratio of medicament microspheres of thymosin and drug release in vitro are calculated.The results show that the average diameter and encapsulation efficiency of the product prepared according to the optimized formulation are 13.8 μm and 80.7%, respectively.The in vitro release behavior within 12 h can be described by the Higuchi equation with T_1/2=295 min.There are no significant changes in size distribution and residual drug contents after being stored at 25 ℃ and 40 ℃ for 90 d, respectively.Due to the fact that its thymosin content and package ratio meet the requirement, and its releasing half life is long, the thymosin-loaded PLA microsphere has a favorable application future.

References:

[1] Lau C Y, Goldstein G.Functional effects of thymopoietin 32-36(TP5)on cytotoxic lymphocyte precursor units(CLP-U).Ⅰ.Enhancement of splenic CLP-U in vitro and in vivo after suboptimal antigenic stimulation[J].J Immunol, 1980, 124(4):1861-1865.
[2] Li Huixiong.Clinic study of thymosin oral delivery system [J].Chinese Pharmaceutical Journal, 1991, 26(4):199-201.(in Chinese)
[3] Finch C A.Ullmann’s encyclopedia of industrial chemistry[M].5th ed.New York:VCH Publisher, 1990:575-585.
[4] Bodmeier R, Chen H, Tyle P, et al.HCl microspheres formulated into an oral suspension dosage form[J].J Controlled Release, 1991, 15(2):65-68.
[5] Zou Liang, Xiao Guomin, Qian Linfa, et al.Preparation and release characteristics in vitro of thymopeptide gelatin microspheres [J].Chinese Journal of Hospital Pharmacy, 2004, 24(9):524-526.(in Chinese)
[6] State Pharmacopeia Commission of China.Chinese Pharmacopeia [M].2nd ed.Beijing:Chemical Industry Press, 2000.(in Chinese)
[7] Drug Management Bureau, Ministry of Health of China.Guide to the clinic study of new drugs [M].Beijing:Chemical Industry Press, 1993:30-32.(in Chinese)
[8] British Pharmacopoeia Commission.British Pharmacopoeia.Vol.Ⅱ[M].London:HMSO, 1993:1280-1281.

Memo

Memo:

Biographies: He Yi(1981—), male, graduate;Xiao Guomin(corresponding author), male, doctor, professor, xiaogm@seu.edu.cn.

Common functions